Hyperhomocysteinemia and transplant coronary artery disease

Transplantation

Volumn 74, Issue 10, 2002, Pages 1359-1364

  Caldera, Angel ^a   Dec, G William ^b  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; VITAMIN;

CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; ENVIRONMENTAL FACTOR; HEART TRANSPLANTATION; HUMAN; HYPERHOMOCYSTEINEMIA; MEDLINE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VASCULAR DISEASE; VITAMIN DEFICIENCY; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION;

EID: 0036852171     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200211270-00001     Document Type: Review

References (50)

1. Hosenpud JD, Bennett LE, Keck BM, et al. The Registry of the International Society of Heart and Lung Transplantation: Eighteenth Official Report-2001. J Heart Lung Transplant 2001; 20: 805-815.
2. Uretsky B, Murali S, Reedy S, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987; 76: 827-834.
3. Gao S, Schroder J, Alderman E, et al. Clinical and laboratory correlates of accelerated coronary artery disease in cardiac transplant patients. Circulation 1997; 76(suppl 5): 56-61.
4. Humphrey L and Blanck T. Anesthetic management of the heart or heartlung transplant patient. In: Baumgartner WA, Reitz BA, Achuff SA, eds. Heart and Heart-Lung Transplantation. Philadelphia, WB Saunders 1998, pp 103-112.
5. Hruban RH, Beschorner WE, Baumgartner WA, et al. Accelerated arteriosclerosis in heart transplant recipients is associated with a T-lymphocyte-mediated endothelialitis. Am J Pathol 1990; 137(4): 871-882.
6. Hammond EH, Yowell RL, Nunoda S, et al. Vascular (humoral) rejection in heart transplantation: Pathologic observations and clinical implications. Heart Transplant 1989; 8(6): 430-443.
7. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261(24): 3561-3566.
8. Escobar A, Ventura HO, Stapleton DD, et al. Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors. Am J Cardiol 1994; 74(10): 1042-1046.
9. Ambrosi P, Garcon D, Riberi A, et al. Association of mild hyperhomocysteinemia with cardiac graft vascular disease. Atherosclerosis 1998; 138: 347-350.
10. Wilcken DEL, Gupta VJ. Sulphur containing amino acids in chronic renal failure with particular reference to homocysteine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest 1979; 9: 301-317.
11. Guttormsen AB, Ueland PM, Svartad E, et al. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997; 52: 495-502.
12. Jacobsen DW. Acquired hyperhomocysteinemia in heart transplant recipients. Clin Chem 44; 11: 2238-2239.
13. Rees MM, Rodgers GM. Association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993; 71: 337-357.
14. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: A common mutation in the methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111.
15. Alpert MA. Homocyst(e)ine, atherosclerosis, and thrombosis. S Med J 1999; 92: 858-865.
16. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep venous thrombosis. N Engl J Med 1996; 334: 759-762.
17. Stampfer MJ, Malinow MR, Willet WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-881.
18. Wald NJ, Watt HC, Law MR, et al. Homocysteine and ischemic heart disease. Arch Intern Med 1998; 158: 862-867.
19. Perry IJ, Refsum H, Morris RW, et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346: 1395-1398.
20. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine and extracranial carotid stenosis. Framingham Heart Study. N Engl J Med 1995; 332: 286-291.
21. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-236.
22. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 5-7.
23. Harker LA, Ross R, Slichter SJ, et al. Homocysteine induced arteriosclerosis: The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-741.
24. Wall RT, Harlan JM, Harker LA, et al. Homocysteinemia induced endothelial cell injury in vitro: A model for the study of vascular injury. Thromb Res 1980; 18: 113-121.
25. Tawakol A, Omland T, Gerhard M, et al. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95: 1119-1121.
26. Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308-318.
27. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11.
28. Rodgers GM, Conn MT. Homocysteine: An atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990; 75: 895-901.
29. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906-1914.
30. Ambrosi P, Barlatier A, Habib G, et al. Hyperhomocysteinemia in heart transplant recipients. Eur Heart J 1994; 15: 1191-1195.
31. Berger PB, Jones JD, Olson LJ, et al. Increase in total plasma homocysteine concentration after cardiac transplantation. Mayo Clin Proc 1995; 70: 125-131.
32. 6 concentrations: Prevalent risk factors for vascular disease in the heart transplant recipients. Transplantation 1998; 65: 544-550.
33. Cook GE, Eaton GM, Whitby G, et al. Plasma atherogenic markers in congestive heart failure and posttransplant (heart) patients. J Am Coll Cardiol 2000; 36: 509-516.
34. Mudd SH, Levy HL. Disorders of transsulfuration. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, eds. The Metabolic Basis of Inherited Disease [Ed. 5]. New York, McGraw-Hill 1983, pp 552-559.
35. Pethig K, Hoffman A, Heublein B, et al. Cardiac allograft vascular disease after orthotopic heart transplantation: Methylenetetrahydrofolate reductase gene polymorphism C677T does not account for rapidly progressive forms. Transplantation 2000; 69: 442-445.
36. Wilkinson AH, Cohen DJ. Renal failure in the recipients of non-renal solid organ transplant. J Am Soc Nephrol 1999; 10:5: 1136-1144.
37. Cole DE, Ross HJ, Evroski J, et al. Correlation between total homocysteine and cyclosporine concentrations in cardiac transplant recipients. Clin Chem 1998; 44: 2307-2312.
38. Arnadottir M, Hultberg B, Vladov V, et al. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 1996; 61: 509-512.
39. Wilcken DEL, Vatsale J, Betts G. Homocysteine in the plasma of renal transplant recipients: Effect of cofactor for methionine metabolism. Clin Sci 1981; 61: 743.
40. Tonstad S, Knudtzon J, Sivertsen M, et al. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr 1996; 129(1): 4-7.
41. Tonstad S, Refsum H, Ose L, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene predisposes to hyperhomocysteinemia in children with familial hypercholesterolemia treated with cholestyramine. J Pediatr 1998; 132(2): 365-368.
42. Finkelstein JD, Martin JJ, Harris B. Effect of nicotinamide on methionine metabolism in rat liver. J Nutr 1998; 188(7): 829-833.
43. Harats D, Yodfat O, Doolman R, et al. Homocysteine elevation with fibrates: Is it a class effect? Isr Med Assoc J 2001; 3(4): 243-246.
44. Lambie DG, Johnson RH. Drugs and folate metabolism. Drug 1985; 30: 145-155.
45. Smulders YM, Spoelstra-de MA, Slaata EH, et al. Trimethoprim-sulphamethoxazole as primary Pneumocystis carinii prophylaxis does not increase serum homocysteine levels in HIV-positive subjects. Eur J Intern Med 2001; 12: 363-365.
46. Kutschka I, Pethig K, Struber M, et al. Homocysteine: A treatable risk factor for allograft vascular disease after heart transplantation? J Heart Lung Transplant 2001; 20: 743-746.
47. Beaulieu AJ, Gohh RY, Han H, et al. Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients. Arterioscler Thromb Vasc Biol 1999; 19: 2918-2921.
48. Cook R, Parker S, Kingsbury K, et al. Effective treatment of hyperhomocysteinemia in heart transplant recipients with and without renal failure. J Heart Lung Transplant 2001; 20: 310-315.
49. Miner SE, Cole DE, Evrovski, et al. Pyridoxine improves endothelial function in cardiac transplant recipients. J Heart Lung Transplant 2001; 20: 964-969.
50. Allen-Auerbach M, Yeung AC, Meredith IT, et al. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year post-transplant. Circulation 1996; 93: 457-462.